It is often suspected (or known) that outcomes published in medical trials are selectively reported. A systematic review for a particular outcome of interest can only include studies where that outcome was reported and so may omit, for example, a study that has considered several outcome measures but only reports those giving significant results. Using the methodology of the Outcome Reporting Bias (ORB) in Trials study of (Kirkham and others, 2010. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. British Medical Journal 340, c365), we suggest a likelihood-based model for estimating the effect of ORB on confidence intervals and p-values in meta-analysis. Correcting for bias has the effect of moving estimated treatment effects toward the null and hence more cautious assessments of significance. The bias can be very substantial, sometimes sufficient to completely overturn previous claims of significance. We re-analyze two contrasting examples, and derive a simple fixed effects approximation that can be used to give an initial estimate of the effect of ORB in practice.
INTRODUCTION
Selective outcome reporting occurs when a subset of the originally recorded outcome variables in a trial are selectively reported in a publication based on their results. When outcome reporting is driven by the significance and/or direction of the effect size (e.g. non-significant outcomes are reported only as p > 0.05, or are suppressed altogether), we refer to this as outcome reporting bias (ORB). For example, in studies looking at bipolar disorders, researchers often examine, as their primary outcome, the time to the first recurrence of any episode, while secondary outcomes include time to the different types of episode (e.g. depression or manic/hypomanic episode). If only the secondary outcomes are found to be significant, authors may not report the non-significant primary outcome. Empirical evidence shows that outcomes that are statistically significant are more likely to be fully reported compared with non-significant outcomes (Dwan and others, 2013) . The ORB in Trials (ORBIT) study examined the prevalence of ORB and its impact on an unselected cohort of 283 Cochrane reviews (Kirkham and others, 2010 ). An output from ORBIT is a nine-point classification system for assessing the risk of bias in those trials within a systematic review where the outcome of interest is either not reported sufficiently for the trial to be included in the meta-analysis, or is not reported at all. Details of the classification system were set out in Kirkham and others (2010, Table 2 ), reproduced here as Table 1 of this paper. Estimates of the reliability of the classification system for detecting bias were given as 88% (7/8, 95% CI 65-100%) for sensitivity and 80% (43/54, 95% CI 69-90%) for specificity. A tutorial for assessing the potential for ORB in a review using the ORBIT classification system is provided in Dwan and others (2010) . The main ORBIT study found that a third of the reviews (34%) contained at least one trial with high suspicion of ORB for the primary outcome. Of 42 reviews claiming a significant result, a sensitivity analysis indicated that 8 (19%) became non-significant after adjustment for ORB and a further 11 (26%) would have overestimated the treatment effect by 20% or more.
The method of sensitivity analysis applied was to calculate the bound for maximum bias (Copas and Jackson, 2006) . This is a method designed to assess the impact of publication bias (the nonpublication of whole studies based on their results) by estimating how many studies it would take to cast doubt on the result of the original meta-analysis and then to determine whether this number of missing studies was plausible. Williamson and Gamble (2007) suggested that a similar method could be used to 372 J. COPAS AND OTHERS assess ORB, using the fact that the application of the ORBIT classification system gives us an estimate of how many studies may have been eligible for inclusion in the meta-analysis but did not report the outcome of interest. However, this method does not take into account the extra information that is known about the eligible studies, including their sample sizes and the level of risk of bias indicated by the ORBIT classification, simply treating them as if they were missing studies about which nothing is known. This method also implies that the missing studies tend to be of smaller size than those with reported results. The aim of this paper is to suggest how ORB can be modeled more explicitly.
MOTIVATING EXAMPLES
The results of the sensitivity analysis for 25 of the reviews included in the ORBIT study were presented in Kirkham and others (2010 , Table 9 ). Here, we present further details on two of these reviews, chosen to illustrate contrasting levels of ORB. For each of these reviews, we summarize the assessment of risk of bias from each of the eligible studies into just three levels as set out in the final column of Table 1 : high risk (classifications A, D, E, and G in the ORBIT terminology), low risk (classifications B, C, F, and H), and no risk (I). High risk means that it is known or suspected that the outcome of interest had been measured but was not reported, either at all or sufficiently well to include in the meta-analysis, because it was found to be non-significant. Low risk means that the outcome of interest may have simply not been measured or otherwise judged less likely to be a source of bias. No risk (I) applies when it is certain that the outcome of interest was not considered and hence the study can safely be ignored.
EXAMPLE 1 Prophylactic use of ergot alkaloids in the third stage of labor (Liabsuetrakul and others, 2007) .
The primary outcome of interest in this review was postpartum hemorrhage (blood loss >500 mL), and the interventions were ergot alkaloids versus placebo or no agents. There were 6 eligible studies but only 4 of these (total 4255 participants) were included in the published meta-analysis, which reported a relative risk favoring ergot of 0.49 with 95% confidence interval (0.26, 0.90). The review concluded that prophylactic intramuscular or intravenous injections of ergot alkaloids are effective in reducing blood loss and postpartum hemorrhage. Two trials were not included in the meta-analysis but when assessed in the ORBIT study one in fact had reported data on one of the groups in the trial. A further three studies were excluded from the review due to "no relevant outcome data", giving 5 studies of concern with a total of 610 participants. Of these, 1 was classified as being at high risk (200 patients) and 4 as low risk (total 410 patients). The modest sample size of the high-risk study suggests that, in this case, the effect of bias may be quite small. EXAMPLE 2 School feeding for improving the physical and psychosocial health of disadvantaged students (Kristjansson and others, 2007) .
The primary outcome of interest was weight gain and the intervention assessed was school meal versus control. The review considered 18 studies but the majority of these were non-RCTs and therefore excluded from this assessment. Of the 6 RCTs, 3 studies (total 1513 participants) were included in the meta-analysis giving a mean difference in favor of school meals of 0.39 kg with a 95% confidence interval (0.11, 0.67). The review concluded that school meals may have some small benefits for disadvantaged children but recommended that further well-designed studies on the effectiveness of school meals are needed. The remaining 3 RCTs (total 6389 participants) did not report the outcome of interest and were all classified as being at high risk of bias. The total number of participants in these high-risk studies is considerably larger than the total for the studies that were actually included in the meta-analysis, suggesting that, in this example, the bias could have a very substantial effect on the validity of the results reported in the original review.
MODEL-BASED BIAS CORRECTION FOR ORB

A model for partial reporting of the outcome of interest
Our aim is to assess the bias caused by the selective reporting of outcomes, allowing for the possibility that outcomes are more likely to be reported if they are found to be statistically significant. The model we suggest assumes that if a paper in the area of interest does not report sufficiently well (or not at all) the particular outcome of interest, then either (i) the outcome was measured but failed to show a significant treatment effect or (ii) the outcome was simply not measured. Omitting such a study from the meta-analysis will lead to a bias in the overall treatment effect in case (i) but not in case (ii). If (i) is known to be true, the bias will be in the direction away from the null, resulting in overestimation of the treatment effect and exaggeration of significance. Suppose that y is the outcome of interest, typically an estimated treatment effect or log relative risk. Figure 1 illustrates the possibilities for a typical study in the area of interest. Starting at the top of the diagram, y may either have been measured (M) or not measured (m). If measured, then we suppose that the trialists will have known whether y was significant (S) or not significant (s). If significant, we assume that y will have been reported (R), but if not significant, then y may have been reported (R) or not reported (r ). If y was not measured, then necessarily y will be unreported (r ).
The two cases mentioned above correspond to the paths on the diagram indicated by the dashed line for case (i) and the dotted line for case (ii). For an unreported study (category r ), it will usually not be known for certain which of these two paths apply, but we assume that, for each trial in category r , we use the ORBIT classification to give the corresponding High/Low risk assessment.
A model for partial reporting of the kind envisaged here needs to specify the probabilities of the various paths in Figure 1 . For y (whether or not it is actually measured), we assume the usual random effects model
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with σ 2 the within-study variance (assumed known) and τ 2 the unknown between-study variance. For the incidence of events M and R, we assume
Here, parameter α is the probability that y is measured, and parameter β is the conditional probability that the outcome is still reported even if it is found to be not significant. The model assumes that significant results are always reported.
We model the uncertainty in the High/Low risk assessments by two reliability parameters
The conditioning events in the definitions of ρ 1 and ρ 2 are the possibilities (i) and (ii) defined above, the paths indicated by the dashed and dotted lines, respectively, in Figure 1 . Ideally ρ 1 = ρ 2 = 1, meaning that all risk assessments are correct. If
, then the classifications are no better than random. Our aim is to look at a sensitivity analysis for values of ρ 1 and ρ 2 in the ranges 1 2 < ρ 1 1, 1 2 < ρ 2 1. We assume throughout that significance is judged at the 5% level (two-tailed), so s means that |y| < 1.96σ . The marginal probability that y is not significant is therefore
where denotes the standard normal cumulative distribution function. Of course, Q = 0.95 if θ = τ 2 = 0.
Likelihood
To find estimates of θ with their associated confidence intervals and p-values, we use maximum likelihood based on the above model. To get the likelihood function, we need to find, for each study being considered in the meta-analysis, the probability of the information that has been observed. The studies naturally divide into four categories: (a) reported significant
We take the categories (a)-(d) in turn:
where f (y) is the density of y under the random effects model (3.1),
For any given values of (ρ 1 , ρ 2 ), the log-likelihood function for the model parameters (θ, τ 2 , α, β) is just the sum of the logs of these expressions evaluated over the observed studies in the categories (a)-(d). Using suffix i to denote individual studies, this gives
where n R is the total number of reported studies and n R∩s is the number of reported studies that are not significant. Each summation in (3.3) means that we add over those studies i within the category given by the suffix of the summation sign.
Estimates, confidence intervals, and p-values
To get maximum likelihood estimates of θ and approximate confidence intervals and p-values from this likelihood, we first find the corresponding profile (or maximized) log-likelihood for θ defined by
For any given pair (ρ 1 , ρ 2 ), the maximum likelihood estimateθ ρ 1 ,ρ 2 is given by finding the maximum of
For further inferences about θ, we use the standard asymptotic result that the distribution of twice the (maximized) log-likelihood ratio for any single value of θ is approximately χ 2 on one degree of 376
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freedom. This implies that the approximate 95% confidence limits (θ
) are given by
Similarly, H 0 : θ = 0 can be tested using the χ 2 statistic
on one degree of freedom, giving the p-value
).
All these quantities can be evaluated numerically from the likelihood (3.3) using standard software (see Supplementary Material).
Special case of correct risk assessments
If it is assumed that the bias risk assessments of all the unreported studies are correct so that ρ 1 = ρ 2 = 1; then the likelihood (3.3) simplifies to
where 5) and, for any event E, n E means the number of studies exhibiting event E. For the profile likelihood for θ , we now only have to maximize out one extra parameter to give
Confidence intervals and p-values follow from this in the same way as in Section 3.3. The remaining terms in (3.4) give separate likelihoods for α and β, giving the estimateŝ
These are the intuitively obvious estimates of α and β when we assume that the risk category High correctly identifies the unreported non-significant studies.
Estimating variances for unreported studies
The likelihood functions (3.3) and (3.5) involve the values of σ 2 for all studies, including the unreported ones. Some information about the unreported variances may be available, but often the only relevant information available for the studies in category r will be the total sample sizes (N ) used in the underlying trials. In this case, the values of σ 2 need to be estimated from the values of N . We assume that, for all of the reported trials, the values of N as well as σ 2 will be known. If y is a sample estimate based on a sample of size N , then in nearly all cases its variance will be inversely proportional to N (other things being equal, if you double the sample size, then you halve the variance). This means that 1 σ 2 = k N, (3.6) for some k. This proportionality constant can be thought of as a "design factor", reflecting the design and circumstances of the trial. For example, if y is the log relative risk for comparing a binary outcome between two treatments, then k depends on the ratio of the sample sizes on the two arms of the trial and on the underlying base rate. This will vary from trial to trial, but if we assume that the average value of k for the unreported studies is similar to that for the reported studies,k R say, then we can estimate σ 2 from (3.6) usingk R as the estimate of k. We takek
Other estimates are also possible, but this is simple and by giving more weight to reported trials with larger values of N , it reflects the fact that in practice there is usually more uncertainty about the true values of σ 2 for the smaller trials.
Assessing the size of reporting bias
To assess the size of bias indicated by the above bias-corrected estimates and confidence intervals, we need to compare these with the corresponding calculations for the random effects model with the unreported studies omitted. Fitting the random effects model to the reported studies alone gives the likelihood
and hence another profile likelihood for θ and resulting asymptotic inferences. This is the likelihood method of fitting the random effects model advocated by Hardy and Thompson (1996) , often giving slightly different estimates and confidence intervals to the more commonly used Dersimonian-Laird method (DerSimonian and Laird, 1986) . See Brockwell and Gordon (2001) for a comparison of these and other methods. As mentioned earlier, the effect of the unreported studies under our model is to shrink the usual metaanalysis estimate of θ toward the null θ = 0. This suggests, for any particular bias-corrected estimateθ, the shrinkage factor
as a simple measure of the relative size of the bias, whereθ RE is the value of θ maximizing the random effects likelihood (3.8). The shrinkage factor K lies between 0 and 1-the smaller K is, the greater is the effect of the bias.
EXAMPLES REVISITED
To fit the model of Section 3, we need the values of y, σ , and the sample size N for each of the reported studies, and the sample size N for each of the high-risk unreported and the low-risk unreported studies. Table 2 sets out these quantities for the two examples in Section 2.
EXAMPLE 1 Here, there are four reported studies and five unreported studies, with θ defined as the log relative risk. The five unreported studies have n High = 1 and n Low = 4. If we ignore the unreported studies altogether and use likelihood L RE (θ, τ ) in (3.8) to fit the random effects model to the four reported studies directly, we get the estimate, confidence interval, and p-valuê
This indicates a significant treatment effect, as found in the published meta-analysis of these studies. If, however, we allow for the further five unreported studies by assuming that their High and Low risk assessments are correct, then we use the likelihood L C (θ, τ ) in (3.5) to give the bias-corrected estimateŝ
As expected, the bias correction has moved the estimate and confidence limits nearer to the null (θ = 0), but only slightly as the shrinkage factor (3.9) of K = 0.937 is here quite close to 1. The treatment effect is still significant but at a slightly more modest level of significance. shows values consistently greater than the uncorrected upper confidence limit. The analysis suggests that the original meta-analysis has exaggerated the treatment effect but not sufficiently to discredit its significance, a conclusion that in this example does not appear to depend very sensitively on the accuracies of the risk assessments, provided ρ 1 is reasonably close to 1.
The dotted lines shown on Figure 2 are discussed in Section 6.
EXAMPLE 2 Here, there are three reported studies and three unreported studies with n High = 3 and n Low = 0. Parameter θ is now the mean difference (in kg) in the children's weight (positive θ means a gain in weight). The random effects (uncorrected) estimates arê
Likelihood L C (θ, τ ) give the bias-corrected estimateŝ
Here, the bias correction is very substantial (K = 0.520), upsetting the previously claimed significance of the treatment effect. The importance of the correction in this case is largely explained by one very large unreported study which has been assessed as high risk. Figure 3 is the analog of Figure 2 for this example. The orientation of these contours shows that ρ 2 is now much more important than ρ 1 , reflecting the fact that all of the unreported studies have been assessed as high risk. The contours increase (less bias) as we move down the plot, lower values of ρ 2 allowing for the possibility that the large high-risk study has been misclassified, although again all contours levels are 380 J. COPAS AND OTHERS nearer the null (smaller) thanθ RE . The treatment effect is not significant when ρ 2 = 1 and only marginally significant if ρ 2 is reasonably close to 1 (say ρ 2 > 0.8, consistent with the sensitivity estimate of 88% reported in Kirkham and others, 2010) .
A SIMPLE FIXED EFFECTS APPROXIMATION TO ORB
If ρ 1 = ρ 2 = 1 (correct risk assessments) and τ = 0 (fixed effects model), then the log-likelihood from (3.5) becomes
The maximum likelihood estimate of θ is the solution of ∂ L(θ)/∂θ = 0, and so ifθ is reasonably close to 0 (the null value), then a standard first-order approximation isθ
, where the fixed effects likelihood L FE is just the first summation in (5.1). Evaluating these derivatives at θ = 0 gives the approximate values of the corrected and uncorrected fixed effects estimates from which we get the corresponding shrinkage factor
If the values of σ 2 for the high-risk studies are estimated from (3.6) with k =k R in (3.7), then this simplifies to
This has a very simple interpretation: the shrinkage factor K is the grand total sample size of the R studies as a proportion of the combined grand total sample size of the R and High studies, discounting the sample size of each High study by the factor 0.241. The discounting reflects the fact that, other things being equal, a study that merely reports that y is not significant provides much less information about θ than a study that fully reports the value of y. Although (5.2) is an approximation, only valid whenθ is close to 0 (when significance of θ in the meta-analysis as a whole is in doubt), it gives at least some guide to the severity of ORB and requires no calculations beyond just adding up the sample sizes of the reported studies and the high-risk studies. By evaluating the corresponding approximations to the variances of these estimates, this also extends to confidence intervals and p-values. We find
The center of the confidence interval shrinks by the factor K , but the width reduces by the factor K 1/2 (closer to 1 than K ). Similarly, if t FE is the t-statistic of the standard fixed effects analysis, the approximate effect of ORB is to reduce the two-sided p-value from 2 (−|t FE |) to 2 (−K 1/2 |t FE |).
These approximations assume that τ = 0 and that the estimates of θ are close to 0, assumptions that are unlikely to hold for either of our examples. However, the approximations still give a rough indication of the severity of ORB. For Example 1, K ≈ 0.988 compared with the random effects shrinkage K RE = 0.937 found earlier. For Example 2, these are K ≈ 0.504 and K RE = 0.520. These fixed effects approximations can be useful in practice since they can be worked out directly from the sample sizes of the individual studies without the need for any of the numerical complexities needed for the likelihood calculations discussed earlier.
THE TOTAL SAMPLE SIZE OF THE UNREPORTED BIASING STUDIES
Section 5 suggests that, at least for the fixed effects model, the biasing effect of the unreported studies depends principally on N Bias , the total of the sample sizes of the "truly biasing" studies, those that follow the event Bias = M ∩ s ∩ r indicated by the dashed line in Figure 1 . The random effects model of Section 3 gives
For any given values of ρ 1 and ρ 2 , we can estimate E(N Bias ) by substituting the maximum likelihood estimates of θ, τ, α, and β into the above formula. The dotted lines on Figure 2 show contours of the estimated values of E(N Bias ) in the first example. The contour levels shown are, from left to right, 500, 400, 300, 200, and 100. As expected, the level at ρ 1 = ρ 2 = 1 is 200, the actual sample size of the single high-risk study in this example. The solid lines are the contours ofθ ρ 1 ,ρ 2 as already discussed in Section 4.1. Both sets of contours are equally spaced. The remarkable similarity between the shapes of these two sets of contours suggests that, for ORB, what is important is not the individual unreported studies and the accuracy of their individual bias assessments, but only the combined sample size of the "truly biasing" unreported studies.
COMMENTS
The model in Section 3 has defined non-significance by a two-tail test-failure to show a clear departure from the null hypothesis in either direction. For some reviews, failure to report the outcome of interest may depend on the direction of the effect size, in which case a one-tail formulation might be more appropriate. Whether a "negative outcome" means a positive or negative value ofθ is again context-specific, for example, whether the outcome of interest is measuring a treatment effect or a harm. The model is easily adapted to one-tail tests by appropriately redefining the probability Q in (3.2).
The ORBIT classification B (reporting only that the result was significant) did not occur in either of the examples in Section 2. Since significance can be in either direction, if B studies do occur, then they are likely to have a much lower risk effect than studies rated as high risk, and so in this sense continuing to take ORBIT category B as Low risk may still be sensible. To explicitly model B as a third risk category, we would need a further link (between S and r ) in Figure 1 , giving a further term in the likelihood. The model would be more complicated but follow the same underlying principles.
Inevitably, the model we have suggested is a simplification of what it is that really determines the partial reporting of outcomes in practice and should only be interpreted as a guide to the size of the biases involved. The assumption that the parameters α and β are constant regardless of the size of the trial may be questionable if there is a large variation across the trial sample sizes. However, the number of studies in a review is often quite small (as in our examples here) and with such limited data available, it is questionable whether attempts to fit more elaborate models will be feasible or meaningful. For this reason, we have treated (ρ 1 , ρ 2 ) as parameters in a sensitivity analysis rather than as parameters to be estimated in the usual way along with the other parameters already in the model. In the related area of publication bias, models that attempt to estimate too many parameters usually end up with confidence intervals that are too wide to give any sensible interpretation (Copas, 2013) . This paper follows the ORBIT methodology of studying the partial reporting of a single outcome of interest, taking no explicit account of how many other competing outcomes might be involved. If there is a clearly defined set of outcomes, then a multivariate approach on the lines of Kirkham and others (2012) might be an alternative approach.
The number of studies identified as unreported (n r ) is likely to be an underestimate in that it does not include relevant studies that remain unpublished or otherwise inaccessible. Copas (2013) gives a likelihood-based model for assessing publication bias, and further work may show how this can be combined with the model discussed here.
CONCLUSION
This paper follows the ORBIT methodology for studying ORB, which is to re-examine those studies that might have been eligible for review but were not included because they did not fully report the particular outcome of interest. Using the summary High/Low risk assessments set out in Table 1 , we have developed a model that reflects the empirical finding that significant outcomes are more likely to be reported than those that are found to be not significant. Our model gives confidence intervals and p-values and hence an estimate of the severity of ORB. The bias correction has the effect of moving the estimated treatment effect toward the null, leading to a more cautious assessment of significance.
The model we propose includes two reliability parameters (ρ 1 , ρ 2 ) describing the uncertainty in the High/Low risk assessments. Our two examples (and others) suggest that the overall bias does not depend very sensitively on the accuracy of these individual risk assessments and that the fitted model with ρ 1 = ρ 2 = 1 (assessments are correct) gives a useful summary. In the first example, the treatment effect remains significant, but in the second example the bias is very substantial, sufficient to overturn the previously claimed significance of the treatment effect.
Further analysis of the model suggests that, as far as overall bias is concerned, all that matters is the total sample size of the studies that should be rated as high risk, rather than the accuracies of any individual risk assessments. This leads to a very simple fixed effects approximation to the severity of ORB.
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